January 12-15 | San Francisco Marriott Marquis
January 12-16 | Virtual
Grace Therapeutics
Grace Therapeutics is a late-stage biopharma with a target PDUFA date of 2Q'26 for GTx-104. GTx-102 ready to initiative pivotal Ph 3. Partnership opportunities including in-licensing CNS, immunology and oncology.